PureTech Health (PRTC) 2020年年度报告「LSE」.pdf

1、P U R E T E C H H E A L T H P L C -A N N U A L R E P O R T A N D A C C O U N T S 2 0 2 0cover_puretech_210315.indd 118/03/2021 14:461 Our Founded Entities are comprised of our Controlled Founded Entities and our Non-Controlled Founded Entities.References in this report to our“Controlled Founded Enti

2、ties”refer to Follica,Incorporated,Vedanta Biosciences,Inc.,Sonde Health,Inc.Alivio Therapeutics,Inc.and Entrega,Inc.References in this report to our“Non-Controlled Founded Entities”refer to Gelesis,Inc.,Akili Interactive Labs,Inc.,Karuna Therapeutics,Inc.and Vor Biopharma Inc.,and,for all periods p

3、rior to December 18,2019,resTORbio,Inc.We formed each of our Founded Entities and have been involved in development efforts in varying degrees.In the case of each of our Controlled Founded Entities,we continue to maintain majority voting control.With respect to our Non-Controlled Founded Entities,we

4、 may benefit fromappreciation in our minority equity investment as ashareholder of such companies.PureTech Health PureTech Health plc(“PureTech Health”,“PureTech”or“the Company”)is aclinical-stage biotherapeutics company dedicated to discovering,developing and commercializing highly differentiated m

5、edicines for devastating diseases,including inflammatory,fibrotic and immunological conditions,intractable cancers,lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders,among others.We have created abroad and deep pipeline through the expertise of our experienced

6、research and development team and our extensive network of scientists,clinicians and industry leaders.Our pipeline,which is being advanced both internally and through our Founded Entities1,is comprised of 26 therapeutics and therapeutic candidates,including 15 that are clinical stage and two that ha